PD-1 blockade using nobilvir in refractory Hodgkin's lymphoma

• 1. 在难治性霍奇金淋巴瘤中用纳武单抗阻断PD-1 [P] . 中国专利： CN109475633A . 2019-03-15
• 2. 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗 [P] . 中国专利： CN109803660A . 2019-05-24
• 3. PD-1 blockade with nivolumab in refractory Hodgkin's lymphoma [P] . 日本专利： JP2019517504A . 2019-06-24

  机译： 顽固性霍奇金淋巴瘤帕金森病PD-1阻滞剂

• 4. PD-1 BLOCKADE WITH NIVOLUMAB IN REFRACTORY HODGKIN'S LYMPHOMA [P] . 欧洲知识产权局专利： EP3463457A1 . 2019-04-10

  机译： PD-1阻断剂与利福单抗治疗难治性霍奇金淋巴瘤

• 5. PD-1 BLOCKADE WITH NIVOLUMAB IN REFRACTORY HODGKIN'S LYMPHOMA [P] . 世界知识产权组织专利： WO2017210453A1 . 2017-12-07

  机译： PD-1阻断剂与利福单抗治疗难治性霍奇金淋巴瘤

• 1. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin [J] . Zhi-Gang Cao, Hong-Wei Zhou, Chao-Jin Peng, 癌症（英文版） . 2013,第009期
• 2. Analysis of Efficacy of DICE (Dexamethasone, Ifosfamide,Cisplatin and Etoposide) Regimen on Recurrent and Refractory Intermediate and High Grade Non-Hodgkin's Lymphoma [J] . Lei Yang, Zhucheng Song, Xiaohong Xu, 癌症生物学与医学（英文版 ） . 2009,第001期
• 3. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series [J] . Beatrice Casadei, Alessandro Broccoli, Vittorio Stefoni, Haematologica . 2019,第11期
• 4. Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [J] . Chong Elise A., Svoboda Jakub, Nasta Sunita Dwivedy, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期
• 5. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J] . Ansell Stephen M., Lesokhin Alexander M., Borrello Ivan, The New England journal of medicine . 2015,第4期
• 6. Autotransplant Approach with Rituximab in High Grade Primary Refractory or Progressive Non Hodgkin's Lymphomas (NHL). 2nd Report [C] . D. Vallisa, A. Lazzaro, R. Berte, European Haematology Association . 2002
• 7. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018
• 8. PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series [O] . Beatrice Casadei, Alessandro Broccoli, Vittorio Stefoni, 2019
• 9. BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL) [O] . R. Chen, A.L. Gibb, G.P. Collins, 2017

• 1. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non- Hodgkin lymphoma: A case report [J] . Zhi-Yun Niu ,Li Sun ,Shu-Peng Wen . 世界临床病例杂志 . 2021,第010期
• 2. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab:A case report [J] . Xiao-Sheng Ding ,Lan Mi ,Yu-Qin Song . 世界临床病例杂志 . 2021,第021期
• 3. Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma [J] . Neelima Vidula ,Andrew M. Evens ,Irene B. Helenowski . 化疗（英文） . 2013,第4期
• 4. 诺维本治疗难治性非霍奇金淋巴瘤 [C] . 欧阳学农 ,陈曦 ,倪敏 . 第七届全国肿瘤药理与化疗学术会议 . 2001
• 5. 程序性死亡蛋白-1(PD-1)抑制剂单药治疗复发/难治淋巴瘤有效性及安全性的Meta分析 [A] . 范潞艳 . 2020